Steady state mice were categorized as responders and non-responders to melanoma immunotherapy treatment.
Stool samples were collected from steady-state mice and subjected to 16S rRNA sequencing. The mice were then treated with either anti-CTLA-4 or isotype control, after which they were retrospectively categorized as control, responder, or non-responder to the anti-CTLA-4 treatment.